Pioneering Finnish Health Tech Firm Delivers a Breakthrough That Amplifies Antibiotic Effectiveness

Koite Health Ltd, a trailblazer in health technology, has reached a game-changing milestone with the granting of a U.S. patent for its groundbreaking innovation aimed at combating one of the most pressing global health crises: antibiotic resistance. This revolutionary technology supercharges the effectiveness of existing antibiotics, reigniting hope in the fight against drug-resistant infections and setting a new standard in global healthcare innovation.

Antibiotic resistance has been described by the World Health Organization (WHO) as one of the greatest threats to global health, food security, and economic development. The overuse and misuse of antibiotics have led to the rise of resistant “superbugs,” rendering many treatments ineffective and putting millions of lives at risk. With infections increasingly defying conventional therapies, the future could see simple ailments spiraling into life-threatening conditions.

A Solution That Turns the Tide

“At Koite Health, we understand the urgency of addressing this crisis head-on. Our patented, light-activated technology doesn’t just fight resistant bacteria—it transforms the way antibiotics work, unlocking their full potential and extending their usability,” said Sakari Nikinmaa, CEO of Koite Health. 

“This innovation offers a new lease on life for existing antibiotics, providing a powerful, sustainable solution when time and resources for developing new drugs are limited,” Nikinmaa added.

The Science of Synergy

Koite Health’s technology is powered by advanced antibacterial photodynamic therapy (aPDT), a state-of-the-art mechanism that works in tandem with antibiotics to break down bacterial biofilms. These biofilms act as protective fortresses for bacteria, rendering conventional treatments ineffective. By dismantling these barriers, the technology ensures that antibiotics can penetrate and destroy even the most resistant bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA).

Transforming Public Health: A New Era in Antibiotic Efficacy

The implications of Koite Health’s innovation are profound and far-reaching:

• Lower Antibiotic Dosages: Reducing required dosages minimizes side effects and the risk of further resistance.
• Tackling Resistant Strains: Restoring the effectiveness of antibiotics against superbugs could close critical gaps in treatment.
• Extending Antibiotic Lifespans: By enhancing existing antibiotics, the technology delays the need for new drug development, saving time and resources.

A Proven Track Record of Innovation

Koite Health has long been committed to fighting bacterial infections while minimizing antibiotic use. Its first product, Lumoral®, is a highly effective, antibiotic-free solution for preventing and treating oral infections, which account for 10% of the world’s antibiotic consumption. With this new patent, the company is expanding its arsenal against bacterial threats.

“Our mission has always been to reduce the reliance on antibiotics and provide better solutions for bacterial infections. This patent takes us a step closer to a world where antibiotics remain effective and accessible,” added Nikinmaa.

A Global Call to Action

Antibiotic resistance already claims over 1.27 million lives annually, and the economic toll is measured in billions. Koite Health’s innovative solution aligns with global strategies to combat this crisis, offering healthcare systems a cost-effective and sustainable way to preserve the effectiveness of life-saving medications.

“This patent represents a pivotal moment for Koite Health and global healthcare. It demonstrates our commitment to leveraging science and innovation to overcome the most significant challenges of our time,” concluded Nikinmaa.

Koite Health is leading the charge in redefining the future of antibiotics—ensuring a healthier, safer world for generations to come.